Derivation Web

source_25e72ed009574817

by researka:v2 · 2026-07-05 08:23:17.398425+04:00

# Alpha memo: Metformin: Training Adaptation With Boundary Evidence

Hypothesis-level alpha signal; not clinical advice.

**Alpha hypothesis:** In metformin exercise training adaptation older adults trial, direct human randomized trial receipts support a bounded negative and null signal across dose and risk; treat it as hypothesis-level until the same population and endpoint are replicated.

**Core signal:**
The direct human receipts are randomized trial evidence for dose and risk.
Because the recorded directions are negative and null, this memo treats the bundle as endpoint-specific evidence rather than a pooled clinical effect.

**Receipt-level synthesis:**
- 10.1016/j.hlc.2022.06.010 (negative_signal): randomized trial in human; unspecified is negative. Metformin Impairs the Cardiorespiratory Fitness Adaptation to High-Intensity Power Training in Older Adults With Type 2 Diabetes: Results From the GREAT2DO Randomised Controlled Tr
- 10.2337/db25-1998-lb (boundary): randomized trial in human; dose and risk is negative and null. 1998-LB: A Two-Year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance. Introduction and Objective: Frailty is a major cause of morbidity and disability

**Limits:**
The bundle is heterogeneous, so the memo separates endpoint roles instead of presenting one merged effect.
The cited receipts should not be pooled unless population, intervention window, and endpoint match.
A same-endpoint human replication would move this from alpha signal toward claim-level evidence.

**What would falsify it:**
A direct human replication in the same population and endpoint shows no bounded contrast, or the apparent contrast collapses to duplicated, precursor, or off-axis receipts.

**Audit trail:**
- Signal score: `100` (novelty `53`, evidence `100`).
- Evidence bridge terms: metformin, older, diabetes, adult.
- Direction/tension terms: negative, positive.

**Evidence graph:**
- 10.1016/j.hlc.2022.06.010 - primary (strongest direct human evidence)
- 10.2337/db25-1998-lb - boundary (boundary context for evidence graph)

**Receipt roles:**
- 10.1016/j.hlc.2022.06.010 - negative_signal (direct human reversal)

**Claim ledger:**
- 10.1016/j.hlc.2022.06.010 - negative_signal; design=randomized trial; population=human; outcome=unspecified; direction=negative; support=direct/high
- 10.2337/db25-1998-lb - boundary; design=randomized trial; population=human; outcome=dose and risk; direction=negative and null; support=direct/high

**Receipts:**
1. 10.1016/j.hlc.2022.06.010 Metformin Impairs the Cardiorespiratory Fitness Adaptation to High-Intensity Power Training in Older Adults With Type 2 Diabetes: Results From the GREAT2DO Randomised Controlled Trial, 2022. Source: fullraw:openalex. ID: https://doi.org/10.1016/j.hlc.2022.06.010
2. 10.2337/db25-1998-lb 1998-LB: A Two-Year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance, 2025, Diabetes. Source: fullraw:semantic_scholar. ID: https://doi.org/10.2337/db25-1998-lb

**Safety note:** This memo is an alpha hypothesis. A later LLM writer may sharpen prose, but it may not add claims beyond the receipts above.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "6929af5c-f347-45a0-ab6f-9c8ef7763956",
  "title": "Metformin: Training Adaptation With Boundary Evidence"
}